Support Alert

Class 4 Medicines Defect Information: Inhixa solution for injection in pre-filled syringe (enoxaparin sodium)

The Medicines and Healthcare products Regulatory Agency (MHRA) has issues a Class 4 medicines defect information drug alert for Inhixa solution for injection in pre-filled syringes. Techdow Europe AB has issued a Direct Healthcare Professional Communication (DHPC) due to rare cases of premature self-activation of the safety device in unused, unopened pre-filled Inhixa syringes. When premature activation has occurred, administration is not possible.

Further details of the alert, the affected products, and action to take are available on the MHRA website.